American Journal of Kidney Diseases
Volume 51, Issue 2 , Pages 184-191 , February 2008

Asymmetric Dimethylarginine and Lipid Peroxidation Products in Early Autosomal Dominant Polycystic Kidney Disease

  • Dan Wang, MD, PhD

      Affiliations

    • Cardiovascular-Kidney-Hypertension Institute, Division of Nephrology and Hypertension and Angiogenesis Section, Lombardi Cancer Institute, Georgetown University, Washington, DC
    • Department of Nephrology, Herlev Hospital, University of Copenhagen, Herlev, Denmark
    • Corresponding Author InformationAddress correspondence to Dan Wang, MD, PhD, 4000 Reservoir Rd NW, Division of Nephrology and Hypertension, Georgetown University, Washington, DC 20007.
    • ,
  • Svend Strandgaard, MD

      Affiliations

    • Department of Nephrology, Herlev Hospital, University of Copenhagen, Herlev, Denmark
    • ,
  • Malene L. Borresen, MD

      Affiliations

    • Department of Nephrology, Herlev Hospital, University of Copenhagen, Herlev, Denmark
    • ,
  • Zaiming Luo, MD, PhD

      Affiliations

    • Cardiovascular-Kidney-Hypertension Institute, Division of Nephrology and Hypertension and Angiogenesis Section, Lombardi Cancer Institute, Georgetown University, Washington, DC
    • ,
  • Stephanie G. Connors, BSc

      Affiliations

    • Cardiovascular-Kidney-Hypertension Institute, Division of Nephrology and Hypertension and Angiogenesis Section, Lombardi Cancer Institute, Georgetown University, Washington, DC
    • ,
  • Qing Yan, BSc

      Affiliations

    • Division of Epidemiology and Clinical Research, National Eye Institute, National Institutes of Health, Bethesda, MD.
    • ,
  • Christopher S. Wilcox, MD, PhD

      Affiliations

    • Cardiovascular-Kidney-Hypertension Institute, Division of Nephrology and Hypertension and Angiogenesis Section, Lombardi Cancer Institute, Georgetown University, Washington, DC

Received 4 April 2007 ,Accepted 27 September 2007.

References 

  1. Gabow PA. Autosomal dominant polycystic kidney disease. Am J Kidney Dis. 1993;22:511–512
  2. Wang D, Iversen J, Wilcox CS, et al. Endothelial dysfunction and reduced nitric oxide in resistance arteries in autosomal-dominant polycystic kidney disease. Kidney Int. 2003;64:1381–1388
  3. Wang D, Strandgaard S. The pathogenesis of hypertension in autosomal dominant polycystic kidney disease. J Hypertens. 1997;15:925–933
  4. Muto S, Aiba A, Saito Y, et al. Pioglitazone improves the phenotype and molecular defects of a targeted Pkd1 mutant. Hum Mol Genet. 2002;11:1731–1742
  5. Wang D, Iversen J, Strandgaard S. Contractility and endothelium-dependent relaxation of resistance vessels in polycystic kidney rats. J Vasc Res. 1999;36:502–509
  6. Wang D, Iversen J, Strandgaard S. Endothelium-dependent relaxation of small resistance vessels is impaired in patients with autosomal dominant polycystic kidney disease. J Am Soc Nephrol. 2000;11:1371–1376
  7. Al-Nimri MA, Komers R, Oyama TT, et al. Endothelial-derived vasoactive mediators in polycystic kidney disease. Kidney Int. 2003;63:1776–1784
  8. Wang D, Braendstrup O, Larsen S, et al. The expression and activity of renal nitric oxide synthase and circulating nitric oxide in polycystic kidney disease rats. Acta Pathol Microbiol Immunol Scand. 2004;112:358–368
  9. Clausen P, Feldt-Rasmussen B, Iversen J, et al. Flow-associated dilatory capacity of the brachial artery is intact in early autosomal dominant polycystic kidney disease. Am J Nephrol. 2006;26:335–339
  10. Borresen ML, Wang D, Strandgaard S. Pulse wave reflection is amplified in normotensive patients with autosomal-dominant polycystic kidney disease and normal renal function. Am J Nephrol. 2007;27:240–246
  11. Kielstein JT, Boger RH, Bode-Boger SM, et al. Marked increase of asymmetric dimethylarginine in patients with incipient primary chronic renal disease. J Am Soc Nephrol. 2002;13:170–176
  12. Torremans A, Marescau B, Kranzlin B, et al. Biochemical validation of a rat model for polycystic kidney disease: Comparison of guanidino compound profile with the human condition. Kidney Int. 2006;69:2003–2012
  13. Caglar K, Yilmaz MI, Sonmez A, et al. ADMA, proteinuria, and insulin resistance in non-diabetic stage I chronic kidney disease. Kidney Int. 2006;70:781–787
  14. Zoccali C, Bode-Boger S, Mallamaci F, et al. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: A prospective study. Lancet. 2001;358:2113–2117
  15. Osanai T, Fujiwara N, Saitoh M, et al. Relationship between salt intake, nitric oxide and asymmetric dimethylarginine and its relevance to patients with end-stage renal disease. Blood Purif. 2002;20:466–468
  16. Kielstein JT, Simmel S, Bode-Boger SM, et al. Subpressor dose asymmetric dimethylarginine modulates renal function in humans through nitric oxide synthase inhibition. Kidney Blood Press Res. 2004;27:143–147
  17. Baylis C, Mitruka B, Deng A. Chronic blockade of nitric oxide synthesis in the rat produces systemic hypertension and glomerular damage. J Clin Invest. 1992;90:278–281
  18. Baylis C. Arginine, arginine analogs and nitric oxide production in chronic kidney disease. Nat Clin Pract Nephrol. 2006;2:209–220
  19. Himmelfarb J, Stenvinkel P, Ikizler TA, et al. The elephant in uremia: Oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int. 2002;62:1524–1538
  20. Aslam S, Santha T, Leone A, et al. Effects of amlodipine and valsartan on oxidative stress and plasma methylarginines in end-stage renal disease patients on hemodialysis. Kidney Int. 2006;70:2109–2115
  21. Oberg B, McMenamin E, Lucas FL, et al. Increased prevalence of oxidant stress and inflammation in patients with moderate to severe chronic kidney disease. Kidney Int. 2004;65:1009–1016
  22. Paisley KE, Beaman M, Tooke JE, et al. Endothelial dysfunction and inflammation in asymptomatic proteinuria. Kidney Int. 2003;63:624–633
  23. Valziri ND. Roles of oxidative stress and antioxidant therapy in chronic kidney disease and hypertension. Curr Opin Nephrol Hypertens. 2004;13:93–99
  24. Tain YL, Freshour G, Dikalova A, et al. Vitamin E reduces glomerulosclerosis, restores renal neuronal NOS, and suppresses oxidative stress in the 5/6 nephrectomized rat. Am J Physiol Renal Physiol. 2007;292:F1404–F1410
  25. Leiper J, Murray-Rust J, McDonald N, et al. S-Nitrosylation of dimethylarginine dimethylaminohydrolase regulates enzyme activity: Further interactions between nitric oxide synthase and dimethylarginine dimethylaminohydrolase. Proc Natl Acad Sci U S A. 2002;99:13527–13532
  26. Knipp M, Braun O, Gehrig PM, et al. Zn(II)-free dimethylargininase-1 (DDAH-1) is inhibited upon specific Cys-S-nitrosylation. J Biol Chem. 2003;278:3410–3416
  27. Boger RH, Sydow K, Borlak T, et al. LDL cholesterol upregulates synthesis of asymmetrical dimethylarginine in human endothelial cells. Circ Res. 2000;87:99–105
  28. Jiang D-J, Jiang J-L, Tan G-S, et al. Protective effects of daviditin A against endothelial damage induced by lysophosphatidylcholine. Arch Pharmacol. 2003;367:600–606
  29. Knipp M. How to control NO production in cells: N(omega),N(omega)-dimethyl-l-arginine dimethylaminohydrolase as a novel drug target. Chembiochem. 2006;7:879–889
  30. Stühlinger MC, Tsao PS, Her JH, et al. Homocysteine impairs the nitric oxide synthase pathway. Circulation. 2001;104:2569–2575
  31. Yin QF, Xiong Y. Pravastatin restores DDAH activity and endothelium-dependent relaxation of rat aorta after exposure to glycated protein. J Cardiovasc Pharmacol. 2005;45:525–532
  32. Iakoubova O, Dushkin H, Beier D. Genetic analysis of a quantitative trait in a mouse model of polycystic kidney disease. Am J Respir Crit Care Med. 1997;156:770–777
  33. Maser RL, Vassmer D, Magenheimer BS, et al. Oxidant stress and reduced antioxidant enzyme protection in polycystic kidney disease. J Am Soc Nephrol. 2002;13:991–999
  34. Torres VE, Bengal RJ, Litwiller RD, et al. Aggravation of polycystic kidney disease in Han:SPRD rats by buthionine sulfoximine. J Am Soc Nephrol. 1997;8:1283–1291
  35. Belkner J, Wiesner R, Kuhn H. Identification of oxidatively modified lipids in atherosclerotic lesions of human aortas. Agents Actions Suppl. 1992;37:S78–S84
  36. Buchanan MR, Haas TA, Lagarde M, et al. 13-Hydroxyoctadecadienoic acid is the vessel wall chemorepellant factor, LOX. J Biol Chem. 1985;260:16056–16059
  37. Spiteller P, Spiteller G. 9-Hydroxy-10,12-octadecadienoic acid (9-HODE) and 13-hydroxy-9,11-octadecadienoic acid (13-HODE): Excellent markers for lipid peroxidation. Chem Phys Lipids. 1997;89:131–139
  38. Martensson J, Groth S, Rehling M, et al. Chromium-51-EDTA clearance in adults with a single-plasma sample. J Nucl Med. 1998;39:2131–2137
  39. Wilcox CS, Lewis PS, Peart WS, et al. Renal function, body fluid volumes, renin, aldosterone, and noradrenaline during treatment of hypertension with pindolol. J Cardiovasc Pharmacol. 1981;3:598–611
  40. Bachorik PS, Ross JW. National Cholesterol Education Program recommendations for measurement of low-density lipoprotein cholesterol: Executive summary (The National Cholesterol Education Program Working Group on Lipoprotein Measurement). Clin Chem. 1995;41:1414–1420
  41. Vallance P, Leone A, Calver A, et al. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet. 1992;339:572–575
  42. Browne RW, Armstrong D. Separation of hydroxy and hydroperoxy polyunsaturated fatty acids by high-pressure liquid chromatography. Methods Mol Biol. 1998;108:147–155
  43. Thomas CE, Jackson RL. Lipid hydroperoxide involvement in copper-dependent and independent oxidation of low density lipoproteins. J Pharmacol Exp Ther. 1991;256:1182–1188
  44. Benvenuti C, Loisance D. Increased serum nitric oxide concentration in cardiac transplantation patients (A marker acute allograft cellular rejection). Transplantation. 1996;61:745–749
  45. Boeger R, Bode-Boeger S, Gerecke U, et al. Urinary NO−3 excretion as an indicator of nitrite oxide formation in vivo during oral administration of l-arginine and l-NAME in rats. Clin Exp Pharmacol Physiol Suppl. 1996;23:S11–S15
  46. Sahai H, Khurshid A. Formulae and tables for the determination of sample sizes and power in clinical trials for testing differences in proportions for the two-sample design: A review. Stat Med. 1996;15:1–21
  47. Agarwal R. Chronic kidney disease is associated with oxidative stress independent of hypertension. Clin Nephrol. 2004;61:377–383
  48. Knipp M, Charnock JM, Garner CD, et al. Structural and functional characterization of the Zn(II) site in dimethylargininase-1 (DDAH-1) from bovine brain (Zn(II) release activates DDAH-1). J Biol Chem. 2001;276:40449–40456
  49. Tojo A, Kimoto M, Wilcox CS. Renal expression of constitutive NOS and DDAH: Separate effects of salt intake and angiotensin. Kidney Int. 2000;58:2075–2083
  50. Nijveldt RJ, Van Leeuwen PA, Van GC, et al. Net renal extraction of asymmetrical (ADMA) and symmetrical (SDMA) dimethylarginine in fasting humans. Nephrol Dial Transplant. 2002;17:1999–2002
  51. Matsuguma K, Ueda S, Yamagishi S, et al. Molecular mechanism for elevation of asymmetric dimethylarginine and its role for hypertension in chronic kidney disease. J Am Soc Nephrol. 2006;17:2176–2183
  52. Welch WJ, Wilcox CS. Macula densa arginine delivery and uptake in the rat regulates glomerular capillary pressure (Effects of salt intake). J Clin Invest. 1997;100:2235–2242
  53. Silbernagl S, Deetjen P. Molecular specificity of the l-arginine reabsorption mechanism (Microperfusion studies in the proximal tubule of rat kidney). Pflugers Arch. 1973;340:325–334
  54. Al BM, Marescau B, Possemiers I, et al. NG, NG-dimethylarginine and NG, NG dimethylarginine in renal insufficiency. Pflugers Arch. 2000;439:524–531
  55. Vallance P, Leiper J. Cardiovascular biology of the asymmetric dimethylarginine:dimethylarginine dimethylaminohydrolase pathway. Arterioscler Thromb Vasc Biol. 2004;24:1023–1030
  56. Cooke JP. Does ADMA cause endothelial dysfunction?. Arterioscler Thromb Vasc Biol. 2000;20:2032–2037
  57. Schachinger V, Britten MB, Zeiher AM. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation. 2000;101:1899–1906
  58. Fliser D, Kronenberg F, Kielstein JT, et al. Asymmetric dimethylarginine and progression of chronic kidney disease: The mild to moderate kidney disease study. J Am Soc Nephrol. 2005;16:2456–2461
  59. Zeier M, Fehrenbach P, Geberth S, et al. Renal histology in polycystic kidney disease with incipient and advanced renal failure. Kidney Int. 1992;42:1259–1265
  60. Yamada SS, Sassaki AL, Fujihara CK, et al. Effect of salt intake and inhibitor dose on arterial hypertension and renal injury induced by chronic nitric oxide blockade. Hypertension. 1996;27:1165–1172
  61. Schaufele TG, Schlaich MP, Delles C, et al. Impaired basal NO activity in patients with glomerular disease and the influence of oxidative stress. Kidney Int. 2006;70:1177–1181
  62. Ravani P, Tripepi G, Malberti F, et al. Asymmetrical dimethylarginine predicts progression to dialysis and death in patients with chronic kidney disease: a competing risks modeling approach. J Am Soc Nephrol. 2005;16:2449–2455

 Originally published online as doi:10.1053/j.ajkd.2007.09.020 on December 28, 2007.

PII: S0272-6386(07)01428-X

doi: 10.1053/j.ajkd.2007.09.020

American Journal of Kidney Diseases
Volume 51, Issue 2 , Pages 184-191 , February 2008

Article Tools